[go: up one dir, main page]

AR055377A1 - Formulacion de inhibidor del factor xa y metodo - Google Patents

Formulacion de inhibidor del factor xa y metodo

Info

Publication number
AR055377A1
AR055377A1 ARP060103576A ARP060103576A AR055377A1 AR 055377 A1 AR055377 A1 AR 055377A1 AR P060103576 A ARP060103576 A AR P060103576A AR P060103576 A ARP060103576 A AR P060103576A AR 055377 A1 AR055377 A1 AR 055377A1
Authority
AR
Argentina
Prior art keywords
factor
inhibitor
formulation
cyclodextrin
beta
Prior art date
Application number
ARP060103576A
Other languages
English (en)
Inventor
Munir N Nassar
Uday S Gogate
Timothy M Malloy
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR055377A1 publication Critical patent/AR055377A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulacion de inhibidor del Factor Xa inyectable la cual incluye el inhibidor del Factor Xa razaxaban o apixaban, un agente de solubilizacion el cual es una beta-ciclodextrina, sustituida, preferiblemente, sulfobutil éter-beta-ciclodextrina (SBE-CD) o hidroxipropil-Beta-ciclodextrina (HPB-CD), y agua. También un método para prevenir o tratar trombosis venosa, trombosis de vena profunda y síndrome coronario agudo que emplea la formulacion anterior.
ARP060103576A 2005-08-17 2006-08-16 Formulacion de inhibidor del factor xa y metodo AR055377A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70907705P 2005-08-17 2005-08-17
US11/464,519 US20070191306A1 (en) 2005-08-17 2006-08-15 FACTOR Xa INHIBITOR FORMULATION AND METHOD

Publications (1)

Publication Number Publication Date
AR055377A1 true AR055377A1 (es) 2007-08-22

Family

ID=37654897

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103576A AR055377A1 (es) 2005-08-17 2006-08-16 Formulacion de inhibidor del factor xa y metodo

Country Status (10)

Country Link
US (2) US20070191306A1 (es)
EP (1) EP1924291A2 (es)
JP (1) JP2009504746A (es)
AR (1) AR055377A1 (es)
BR (1) BRPI0614827A2 (es)
CA (1) CA2619214A1 (es)
MX (1) MX2008002057A (es)
PE (1) PE20070378A1 (es)
TW (1) TW200800270A (es)
WO (1) WO2007022165A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2900243T3 (es) 2008-10-22 2022-03-16 Array Biopharma Inc Compuestos de pirazolo[1,5-a]pirimidina sustituidos como inhibidores de trk quinasa
SMT202000093T1 (it) * 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
JP5846647B2 (ja) 2010-02-25 2016-01-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アピキサバン製剤
CN110917130A (zh) * 2012-06-27 2020-03-27 武田药品工业株式会社 用盐稳定的胺和有机酸的液体制剂
CN104736142B (zh) * 2012-09-26 2020-03-03 百时美-施贵宝控股爱尔兰无限公司 阿哌沙班液体制剂
CN104650072B (zh) * 2013-11-18 2016-03-16 成都苑东生物制药股份有限公司 一种吡啶类衍生物
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
HUE068971T2 (hu) 2016-04-04 2025-02-28 Loxo Oncology Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid folyékony készítményei
PT3800189T (pt) 2016-05-18 2023-07-27 Array Biopharma Inc Preparação de (s)-n-(5-((r)-2-(2,5- difluoropenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroxipirrolidina-1-carboxamida
CN115715770B (zh) * 2021-08-24 2024-01-26 新领医药技术(深圳)有限公司 阿哌沙班透皮贴剂及其制备方法
WO2023072967A1 (en) 2021-10-27 2023-05-04 Pharma-Data S.A. Apixaban suspension and preparation method
NL2029536B1 (en) 2021-10-27 2023-05-26 Pharma Data S A Apixaban suspension and preparation method
WO2026003874A1 (en) * 2024-06-28 2026-01-02 Cipla Limited Injectable compositions of apixaban

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US4745105A (en) * 1986-08-20 1988-05-17 Griffin Charles C Low molecular weight heparin derivatives with improved permeability
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
FR2773801B1 (fr) * 1998-01-19 2000-05-12 Sanofi Sa Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant
BR0013926A (pt) * 1999-09-13 2002-07-23 Dimensional Pharm Inc Inibidores de serina protease de azacicloalcanona
TWI331526B (en) * 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CN101357914A (zh) * 2001-09-21 2009-02-04 百时美施贵宝公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂

Also Published As

Publication number Publication date
WO2007022165A3 (en) 2007-08-23
MX2008002057A (es) 2008-04-16
PE20070378A1 (es) 2007-05-04
EP1924291A2 (en) 2008-05-28
JP2009504746A (ja) 2009-02-05
WO2007022165A2 (en) 2007-02-22
WO2007022165B1 (en) 2007-10-18
CA2619214A1 (en) 2007-02-22
BRPI0614827A2 (pt) 2011-04-19
TW200800270A (en) 2008-01-01
US20090291913A1 (en) 2009-11-26
US20070191306A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
AR055377A1 (es) Formulacion de inhibidor del factor xa y metodo
CY1122685T1 (el) Μορφες δοσολογιας της απιξαμπανης
AR116859A2 (es) Métodos para tratar la esclerosis múltiple progresiva
CL2008003653A1 (es) Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
AR040887A1 (es) Formulacion y metodo de complejo de aripiprazol
AR054470A1 (es) Aditivo de perdida de fluido para una limpieza de fractura mejorada
CL2008002960A1 (es) Método para producir 2-ceto-3-desoxi d-gluconato (kdg), basado en proporciopnar acido-desoxi l-eritro hexocelulosa uronico (dehu), y contactar dicha molecula con un microorganismo recombinante que codofica una dehu-hidrogenasa.
AR032643A1 (es) Combinaciones de inhibidor(es) de absorcion de esterol con agente(s) cardiovascular(es) para el tratamiento de condiciones vasculares
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
ECSP088238A (es) Proceso y equipo para mejorar las propiedades de flujo del petróleo crudo
AR055351A1 (es) Metodos y composiciones para el control de finos de formacion y para la reduccion de reflujo de agente de sosten
CO4920246A1 (es) Composicion liofilizada que comprende epotilona a y b con manitol o ciclodextrina .
CY1109295T1 (el) Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
CL2004001415A1 (es) Composicion polimerica en estado fundido que comprende un polimero de hidroxilo como almidon o sus derivados y un agente de entrecruzamiento; metodo para preparar la composicion; fibra que la comprende; estructura fibrosa que incluye la fibra y produ
NO20062211L (no) Korrosjonsinhibitorforsterker og fremgangsmate for anvendelse av denne
AR073204A1 (es) Tratamientos de bananas.
AR109263A2 (es) Composición que comprende moxidectina
BR112018000611A2 (pt) composição de limpeza espumante, e, método de limpeza para remover sujeira e/ou detritos.
CL2007002026A1 (es) Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica.
AR054243A1 (es) Metodos y composiciones para retardar la liberacion de quimicos de tratamiento
AR065564A1 (es) Composiciones farmaceuticas que comprenden un agente calciletico
AR039664A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan
AR122491A1 (es) Agente preventivo de adhesión y método preventivo de adhesión usando el mismo
BRPI0607003A2 (pt) forma de dosagem com liberação sustentada e método para liberação sustentada de um composto de pirazina substituìda
AR054909A1 (es) Modulacion de los receptores activados por el proliferador de peroxisomas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal